September 26, Tuesday
08:00
Registration Open & Badge pick-up
09:00 – 09:30
- Ana Polanco, President Asebio
- Roger Torrent i Ramió, Minister of Business and labour, Goverment of Catalonia
- Xiana Margarida Méndez Bértolo, SEC. STATE OF COMMERCE Dª.
- Jaume Collboni, Mayor of Barcelona
09:30 – 10:15
Sponsor HIPRA
Abstract
The veterinary biotech HIPRA has achieved the milestone of developing a vaccine against COVID-19 In 2020, in a pandemic context caused by COVID-19, HIPRA took on a new challenge using its long-standing expertise in vaccines: to develop a vaccine against the coronavirus. In 2021, it created the new Human Health Division and acquired GoodGut, a biotechnology start-up dedicated to research and development of diagnostic tests for digestive diseases. On 30 March 2023, the European Medicines Agency (EMA) and European Comission recommended that a marketing authorisation be granted for the COVID-19 vaccine developed by HIPRA, named BIMERVAX®. It is a bivalent adjuvanted vaccine containing a recombinant protein based on the Beta and Alpha variants of SARS-CoV-2 and is indicated as a booster dose for people 16 years of age or older. This antigen is accompanied by an adjuvant that enhances the immune response. To date, it is the only Spanish vaccine against COVID–19 and is one of the eight vaccines that compose the European Union’s SARS-CoV-2 immunisation portfolio.
Elia Torroella Busquets, Executive R& D Vicepresident at Hipra (Spain)
10:15 – 11:00
Sponsor
Abstract
Europe needs to scale up its biomanufacturing capacities and performance, maximizing the benefits of the industry while minimizing its environmental footprint. This panel will focus on the transformative role of biomanufacturing in shaping the future of Europe and ensuring the sustainability of the bioproduction industry. Regulatory and reimbursement pathways, new approaches to investment, upskilling and reskilling workforce and adoption of sustainable solutions are some of the topics that will be discussed in this engaging round table that will provide insightful strategies, take-home learnings and dynamic exchanges among experts and attendees.
Moderator
- Anaïs Le Corvec CEBR and member of HERA Joint Industrial Cooperation Forum (JICF)
Panelists
- Nerea Garcia, Site Director at Reig Jofré (Spain)
- Hilary Stiss, Senior Manager for International Affairs, Biotechnology Innovation Organization (USA)
- Sara Secall, Partner at Inveready (Spain)
- Claire Skentelbery, Director general EuropaBio and member of HERA Joint Industrial Cooperation Forum (JICF) (Belgium)
- Damaso Molero, CEO 3P BIO Pharmaceuticals (Spain)
Sponsor
Abstract
The European Commission proposed in July 2023 a legal framework for plants obtained by targeted mutagenesis and cisgenesis. This new framework will establish the playing field for plant innovation in Europe for the next generation and will impact on European food production as well as to the goals of the European Green Deal and “Farm to Fork” Strategy. Moreover, as the first piece of legislation regulating these techniques and the products obtained through them, it will potentially shape the future of such techniques for other applications.
In this roundtable, panelists will discuss about the key elements of the proposal, its likely impact on plant innovation and its contribution to the safety and sustainability of the European food chain.
Purpose:
The session will highlight the impact the proposal of the Commission could have on plant innovation in Europe, advocating for an innovation enabling approach to regulating these techniques both for plants and other organisms.
Moderator:
- Richard Borreani, Public Affairs, Science & Sustainability Manager, Bayer Crop Science Iberia
Speakers:
- Diego Orzaez Calatayud, Senior Researcher at CSIC and member of the NGT expert group of the National Biosecurity Commission (CNB)
- Antonio Granell, Research Professor at CSIC
- Jesús López Colmenarejo, General Manager at the publishing group Editorial Agrícola- Henar Comunicación Agroalimentaria
- Esther Esteban Rodrigo, General Manager at the National Agriculture and Food Research and Technology Institute (INIA-CSIC)
- Mar Fernández, General Manager at the Spanish Association of Egg Producers (ASEPRHU)
Sponsors
Abstract
This round table with leading agents of the Spanish Government funding agencies will highlight the value of an activity whose weight in the national economy is increasing by dint of the tremendous involved in its development. We will engage in a conversation which will showcase how each of the Public Administrations is accelerating innovation in the sector, what remains to be done and how, thanks to the new Startups and Digital Nomadism law, the offer of emerging companies will be able to provide response to society’s needs as never before and position our country as a beacon of Innovation, knowledge and health.
A conversation with:
- José Bayón, CEO at ENISA- Spanish National Innovation Company-. Ministry of Industry, Trade and Tourism (Spain)
- José María Blasco Ruiz, Head of Infrastructures, Health and ICT in ICEX Spain Trade and Investment (Spain)
- Juan Antonio Tébar, Director of European Programmes and Regional Cooperation at CDTI (Spain)
Sponsors
Abstract
Precision oncology involves molecular profiling of tumors to identify targetable alterations, genomic testing –including next-generation sequencing (NGS) and other platforms and technologies to identify tumor specific genetic alterations and prescribe an appropriate personalized therapeutic recommendation, leading to more effective and safer treatments, thus increasing chances of success and survival. Targeted oncology drugs, such as monoclonal antibodies, provide further rationale for developing these approaches.
In this round table companies leading efforts in personalized oncology provide a review of the state of the art and examine the many opportunities that novel platforms open for the future of oncology.
Moderator:
- Elena Sánchez Viñes, COO at Amadix (Spain)
Speakers:
- Cristina Nadal, Executive Policy Director, MSD (Spain)
- Miquel Balcells, Exec. Medical Director at Amgen (Iberia)
- Manuel Vázquez, Principal, Consulting Iberia AT Alira Health (Spain)
11:00 – 11:30
Coffee Break
11:30 – 12:00
Presenter:
- Isabel Núñez
Speakers:
- Kristin Schreiber, Director: Directorate Ecosystems I: Chemicals, Food, Retail, Health in DG Grow, the Directorate General for Internal Market, Industry, Entrepreneurship and SMEs (Germany)
12:00 – 13:00
Sponsor
Abstract
Europe has significant strengths – an open, diverse and collaborative mindset, a leadership in publication of scientific papers, some of the world’s top scientists and excellent academia. The biotech sector has also seen an increase in attracting public and private capital. At the same time, remaining fragmentation – whether in its scale-up, human resources and financing – is holding it back in achieving sustained global leadership in lifesciences and compete against the United States and China. The data shows that Europe is losing ground. Today there are half as many ATMP clinical trials in Europe than there are in the US and three times fewer than in China. Translation remains the biggest challenge in Europe, despite progress in attracting capital.
Policy makers at national and EU level need to understand what truly constitute Europe’s strengths, how to build and maximise on these so that biotech companies and investors can thrive in Europe. Solutions need to be pragmatic, tailored to the European context.
One area that remains undervalued is the ability to build co-localised hubs.
When looking at the biotech cluster in the US, one of its drivers of its success is the rich mix of top academic institutions, scientists and industry – with both smaller biotech companies and ‘big pharma’ but also because of solid technology transfer mechanisms in place that allow rapid translation of new inventions from academic labs into commercial R&D and a dynamic investment community that is willing to take risks with their investment, driven by the confidence that success brings high rewards.
The session will seek to explore whether Europe is today closer to being able to build similar biotech clusters as exists in the US, whether the technology available today, collaborative and coordinated approaches, clear goals, and existing funding efforts are enough for Europe to fulfill its potential for innovation and leverage resources at scale. It will also touch on the current ecosystem in Europe, how this is evolving and what level of clarity and predictability it offers investors to see a clear path from scientific discovery to patient access.
This session seeks to bring together different perspectives – from venture capital, finance, industry and biotech clusters – to identify the shifts needed and key drivers of success to fully draw on the benefits of an innovation hub model.
Moderator:
- Montserrat Daban, Director of Science Policy and Internationalisation in Biocat and President of the Council of European BioRegions (Spain)
Speakers:
- Cristobal Belda Iniesta, Director of the Carlos III Health Institute (Spain)
- Angel Cedazo-Mínguez, VP Strategic Initiatives & Scientific Relations Europe Sanofi – (Spain)
- Montserrat Vendrell, Partner at Alta Life Science (Spain)
Sponsor
Abstract
The quest to discover novel therapeutic approaches for rare diseases, most of which are of genetic origin, continues at a steady pace despite the daunting challenges encountered when addressing their treatment. This session will showcase examples from some of the relevant players that are currently committed to deliver new solutions for these patients inspired by their large unmet need: a public – private collaboration led by the pharmaceutical industry, the experience of a successful biotech, and the perspective from an expert clinician, representing the link to patients that continue to bear the real burden of these, in many cases, devastating diseases.
Moderator:
- Anna Planagumà, PhD, Licensing Manager, External Innovation and Licensing Almirall, (Spain)
Speakers:
- Arsenio Nueda, Project & Alliance Manager R&D, Almirall (Spain)
- Marc Martinell, CEO & co-founder Minoryx (Spain)
- John McGrath, Head of the Genetic Skin Disease Group King’s College London (UK)
Abstract
Explore the role of biotechnology in transforming the food industry in a discussion about the opportunities and challenges associated with the next frontier of food.
Moderator:
- María Jesús Latasa Sada, Head of Innovation and Education at IMDEA Food, (Spain)
Speakers:
- Ana Isabel Gonzalez – CEO at Protiberia: how to produce protein in a sustainable way, without waste, and with an almost-zero carbon footprint through the insect industry.
- Daniel Gómez-Bravo – CEO at Bread Free: how biotechnology can improve can be applied to change the properties of food, offering opportunities for improving food quality, increasing nutritional value, extending shelf life, and catering to specific dietary needs or preferences.
- Miguel Ángel Cubero – CEO of Ingredalia: how to produce protein in a sustainable way, without waste, and with an almost-zero carbon footprint through food waste valorization.
- Mariano Oto – CEO of Nucaps: how biotechnology can provide precision and personalized food that improves food quality and nutritional benefits, while also being sustainable.
Sponsors
Abstract
As more gene therapies are approved by the FDA and EMA it is now
becoming clear that gene therapies are the medicine of the future. The
FDA expects more 10-20 approvals yearly based on the current clinical
stage pipeline. Challenges however can be daunting. More precise gene
editing tools, such as CRISPR-CAS9 to avoid off-target and secure precision
insertions are critical for the safety and efficacy of the new therapies.
Therapies treating rare diseases need to overcome pricing and
reimbursement challenges for healthcare providers. GMP manufacturing
of vectors and DNA needs to be process robust, scalable, and capable of
delivering in the required timelines.
In this roundtable we meet some of the protagonists of this revolution in
Spain and abroad. Syngoi has developed scalable methods for synthesis of
covalently close DNA sequences. Integra is creating next-generation gene
writing tools to boost the efficiency and safety of advanced therapies.
Canadian company Jenthera offers a novel cell-targeted nuclease
approach for therapeutics that address the fundamental challenges faced
by CRISPR-based gene editing. Alira Health provides global consulting and
clinical services enabled by technology and real-world evidence.
Moderator:
Javier García Cogorro, Managing Partner at Columbus Venture Partners
Speakers:
- Ana Ricobaraza, Syngoi (Spain)
- Joris Pezzini, EVP Biopharma Health, Alira Health (Spain)
- Avencia Sánchez-Mejías, CEO at Integra Therapeutics (Spain)
- Philip Roche, Founder, CEO and CSO at Jenthera Therapeutics and inventor of the novel gene editing technology (Canada)
12:30 – 13:00
Speakers:
- Sara García Alonso: ESA Austronaut reserve & molecular biologist at
Centro Nacional de Investigacoines Oncológicas (Spain)
13:00 – 13:45
Sponsor
Abstract
Gene delivery via viral vectors can be achieved utilizing two different methods: ex-vivo and in-vivo. Lentiviral vectors are typically used for ex-vivo delivery and are ideal when the cells causing the disease can be extracted, corrected in a laboratory setting, and introduced back into the patient.
In addition, there is a clear trend showing an increase in the use of lentiviral vectors in-vivo. In these therapies the vectors themselves constitute the pharmaceutical product.
In this session you will learn more about the efficiency of lentiviral vectors when delivering genetic material both ex-vivo and in-vivo, and the success of various companies after their administration: CellPoint, a Galapagos Company, a Dutch CAR-T therapies company that disrupts the time-to-treatment of these therapies, Theravectys, a French immunotherapy company who is developing an extensive pipeline of vaccine candidates, and One Chain Immunotherapeutics, a Catalan company which aims to develop CAR-Ts to treat oncological diseases.
VIVEbiotech is a CDMO developing and GMP manufacturing lentiviral vectors according to both EMA´s and FDA´s standards. VIVEbiotech is manufacturing vectors for more than 30 US, European and Asian companies, and is accredited for manufacturing lentivectors to be administered both ex-vivo and in-vivo. The company recently expanded facilities what allowed significantly increasing our production capacity being able to provide good slots availability from early-stage to clinical and commercial-scale batches. https://www.vivebiotech.com/en/.
Cellpoint was founded in 2018 and is developing an impressive pipeline of ex-vivo Car-T therapies, using a decentralized point of care manufacturing, with several candidates in very advanced stages. Cellpoint was acquired by Galapagos NV in 2022. Cellpoint/Galapagos combines a novel CAR-T delivery model with cutting-edge antibody capability. https://cellpoint.bio and https://www.glpg.com.
TheraVectys is a spin-off of the Institut Pasteur pioneering the application of novel lentiviral vector technology to develop treatments and prevention of cancers and infectious diseases. Their lentiviral vector-based immunotherapy induces unprecedented, high-quality T-cell and antibody responses, generating strong and long-term protective or therapeutic immunity. Their Lenti-HPV-07 vaccine candidate against cervical and oropharyngeal cancers to be administered in-vivo will soon be tested in a Phase I/IIa clinical trial in the US. https://www.theravectys.com/.
One Chain Immunotherapeutics is a spin-off company of the Josep Carreras Leukemia Research Institute and the Catalan Institution for Research and Advanced Studies (ICREA). It was created in 2020 and is based on research led by the team of Dr. Pablo Menéndez which consists of the development of an innovative pipeline of CAR-T therapies. https://www.onechaintx.com/
Moderator:
- Gurutz Linazasoro, CEO, VIVEbiotech (Spain)
Speakers:
- Natalia Elizalde, PhD, Chief Business Development Officer, VIVEbiotech (Spain)
- Joost van den Berg, PhD, Head of Process Development, CellPoint, a Galapagos Company (Netherlands)
- Pierre Charneau, PhD, Founder & Chief Scientific Officer Speaker Theravectys (France)
- Pablo Menéndez, PhD. Founder of One Chain Immunotherapeutics, Principal Investigator at Josep Carreras Leukemia Research Institute & ICREA Professor (Spain).
Sponsor Klinea
Abstract
The evolution from the start-up to an industrial plant: technology requirements, fund raising and regulatory requirements.
- Economical strategy to fund:
- Product development
- Industrialisation
- Production facility
- Process scale-up (lab to manufacturing)
- Modular automation strategy
- Engineering design
- Qualification and validation
- Regulatory assessment
Klinea BioPharmaceutical Engineering
Klinea is a biopharmaceutical engineering company focused on process knowledge to enhance the best facility design.
Klinea has subject matter experts with 20+ years of accumulated experience in biopharma engineering providing the expertise to deliver excellence on:
- Facility design and construction management
- Bioprocess optimization and industrialization
- Digital transformation
- Sustainability
Sanpi inversions
Limited company founded in 2018 that acts as angel investor, provides consulting services in the areas of fundraising and strategic development and mentors founders in the Spanish biotech ecosystem in their scale-up processes.
LeanBio
Leanbio is a market oriented CDMO that develops and manufactures biopharmaceutical products as New biological entities and Biosimilars. Leanbio covers full value chain of services in the development and manufacture of biotherapeutics from gene to vial.
Ysios Capital
Ysios Capital provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.
COPA-DATA
COPA-DATA, as independent manufacturer of software, enables industrial automation, digitalization and progress in industries such as pharmaceuticals & life sciences. The zenon Software Platform is a modular industrial control automation system, working completely vendor-independent in any hardware and software environment.
Bionet
Bionet is a provider of bioprocessing technology and services. Bionet accompanies its biotech clients from the R&D to the industrial production settings with the ultimate goal to achieve the productivity and profitability goals of their bioprocesses.
Moderator:
- Jordi Gibert, Head of Biotechnology Unit at Klinea (Spain)
Speakers:
- Claudia Jimenez, Managing partner at Sanpi inversiones (Spain)
- Albert Font, CEO at LeanBio (Spain)
- Guillem Laporta, Partner at Ysios Capital (Spain)
- Giuseppe Menin, Director Life Science and Process Industry at COPA-DATA (Italy)
- Ricardo Egea, CEO at Bionet (Spain)
Sponsors
Abstract
The use of artificial intelligence (AI) has great potential in the pharmaceutical industry and is indeed already shaping the future of healthcare. Opportunities exist in drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, and market access among others. In this session we approach AI from different angles looking at applications at all stages: from target discovery and early drug development to clinical studies, to market access and pharmacoeconomic studies. French firm Owkin is combining cutting-edge machine learning and medical knowledge to advance drug discovery, develop diagnostics tools and de-risk clinical studies. Nostrum Biodiscovery is a spin-off company of the Barcelona Supercomputing Centre that is developing Cloud-based Molecular Modelling and Artificial Intelligence technology, powered by a Montecarlo algorithm, for Drug Discovery, Enzyme Engineering and Nucleic Acids. Biotechnology firm Amgen has been investing in the power of artificial intelligence (AI), data science and other technologies to create the next generation of medicines that will bring the most value to patients and anticipates a sound impact of AI in the access process of innovation.
Moderator:
- José María Giménez Arnau, Chief Scientific & Medical Officer, Esteve (Spain)
Speakers:
- María Fernández, Market Access Director, Amgen (Spain)
- Francisco Miguel Torres, Principal Partnerships Manager Spain, Owkin (France)
- Alexis Molina, Director of Artificial Intelligence at Nostrum Biodiscovery (Spain)
Sponsor
Abstract
The past pandemic-dominated years have delivered a lifetime of lessons. The pandemic illuminated the power of meaningful collaborations between pharma and biotech companies and how they propel outcomes for public health, from research and development to commercialization and distribution. And even though Pharma have been partnering with emerging biotechs for decades, the world has now seen how pairing technology and infrastructures from one company with experimental therapies from another can get successful innovation to patients much faster than was ever imagined. Large pharma companies rely on innovative start-ups to discover and develop new drugs, which they often later acquire to complete the clinical development and commercialize the approved drug. This panel will discuss the different routes that biotechs could explore for partnering with pharma companies paving the way for stronger biotech-pharma alliances. The panel will draw on the experiences of entrepreneurs, pharma, and venture capital professionals.
Moderators:
- Francisca Peixoto, Investment Manager, LifeLink Ventures (Spain)
- Ruben Sebastian-Perez, Associate , Caixa Capital Risc (Spain)
Speakers:
- Jesús Baena, Global BD&L Partnering Director, Novartis (Switzerland)
- Hans Christian Keller, Chief Business Officer, Minoryx Therapeutics (Spain)
- Esther Melo, Director BD&L , Roche Pharma Partnering (Switzerland)
- Oscar Pérez, Chief Marketing, Pricing & Market Access and Business Development Officer, Ferrer (Spain)
13:45 – 15:00
Lunch Break
15:00 – 16:00
Sponsors
Abstract
Advanced therapy medicinal products (ATMPs) are innovative therapies that encompass gene therapy, somatic cell therapy, and tissue-engineered products. ATMPs are highly personalized but potentially highly effective and even life-saving treatments. Two Spanish regions have developed ambitious strategies to foster and impulse ATMPs. Speakers in this round table will analyze actions to develop the ecosystems in the Gipuzkoa (Basque Country) and Catalonia.
Moderator:
- Ángel Sánchez, Partner at SILO (Spain)
Speakers:
- Robert Fabregat, CEO, Biocat (Spain)
- Núria Montserrat, Principal investigator, Institute of Bioengineering of Catalonia (IBEC) (Spain)
- Itziar Vergara, Chief Scientific Officer at Biodonostia-GANTT (Spain)
- Iraida Loinaz, Director of the CIDETEC Institute for Nanomedicine (Spain)
Sponsors
Platinium
Gold
Abstract
The development of a mature and rich biotech ecosystem requires a diverse base of companies that provide financing, incubator space and contract development and manufacturing organizations. In this round table we examine how some well-established as well as new entrants are creating the solid infrastructure required to make Spain a leading internationally competitive ecosystem. Although Spanish biotechnology has progressed by leaps and bounds there may be some gaps in the ecosystem. In this round table we will try to identify if all the gaps in our system have been plugged or if we are still lagging other biotech powers and contrast with experiences abroad. Our panel will review past achievements, current capabilities, and potential investment opportunities.
Deeplabs/MASID Deep Labs offers scientific infrastructure, capital, and advice to help companies grow and achieve their full potential. Following the global trends DeepLabs has established MASID, the first private Life Science campus in Spain offering more than 50,000 sqm that house a mix of laboratories, work spaces, coworking and coliving spaces.
Parc Científic de Barcelona is one of Europe’s leading life-sciences R&D ecosystems with more than 100,000 sq. meters and 125 phama, biotech, foodtech and cosmetics companies as well as public research centers.
PEI BioAlliance includes over 65 bioscience companies, several research institutions, and is home to Emergence – Atlantic Canada’s Bioscience Business Incubator and Natural Products Canada, North America’s first business accelerator dedicated to the commercialization of products and technologies based on natural product chemistry.
Asabys is one of the leading VC funds specialized funds with a portfolio of 14 biotechnology startups.
Moderator:
- Paula Arnaldo, Manager at Bioinnova Consulting (Spain)
Speakers:
- Maria Terrades, CEO of Parc Científic de Barcelona (Spain)
- Josep Sanfeliu, Co-founder and managing partner of Asabys (Spain)
- Felipe Morenés, Co-founder, Deep Labs & Masid (Spain)
- Rory Francis, CEO at PEI BioAlliance (Canada)
Sponsor
Abstract
Albeit young, the Spanish life sciences ecosystem already has some interesting case studies of relationships between biotech start-ups and pharmaceutical companies, from early research collaborations to M&A. Venture capital-backed biotech start-ups and larger corporations are joining forces for preclinical or clinical stage development to bring innovative products to the market and provide new treatment options to patients in need. In this panel we will discuss the best practices and lessons learned of some of these collaborations, and how they contribute to value generation for all stakeholders.
Moderator:
- Karen Wagner, Managing Partner,Ysios Capital (Switzerland)
Speakers:
- Khatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSD (UK)
- Miguel Barrero Durán, Corporate Head Business Development & Innovation at Neuraxpharm Group (Spain)
- Hans-Christian Keller, Chief Business Officer Minoryx (Denmark)
Sponsor
Abstract
Highlighting Argentina’s Biotechnology Prowess in the Public and Private Sectors In the spotlight at BIOSPAIN 2023 will be Argentina, showcasing its robust biotechnology capabilities across both public and private domains. This event aims to elevate awareness of Argentina’s excellence in the biotechnology sector.
Speakers:
Public Sector
- Ricardo Alfonsín, Argentine Ambassador to Spain
- Rossana Surballe, Ambassador, General Consul and Director of the Argentine Promotion Center in Barcelona
- Sebastián Laino, National Director of Knowledge Based Services at the Ministry of Foreign Affairs in Buenos Aires
Private Sector
- Valentina Carricarte, Representative of the Argentine Biotechnology Chamber (CAB)
MORE TBC
Keynote session 3: Vida a la Biotecnología - 16:00 – 17:00
Sponsor
Abstract
The panel will discuss the current challenges on the development of innovative drugs in mental health and the feasibility to approach the unmet medical needs faced with a personalized approach. Some topics discussed will be:
- Prevalence and impact of mental conditions on the current society
- Challenges in clinical investigation in Mental Health
- Current innovations in depression, personality disorders, and psychotic disorders.
- The need to understand and focus on the patient. Roles of Patient Advocacy Groups
- Advances in understanding and treating Neurodevelopmental disorders (NDD)
- Can we learn from NDD to accelerate personalized medicine in mental disorders?
- BPD as an example of the difficulty of psychiatric diseases. Is BPD treatable?
Session sponsor: ORYZON
Moderator:
- Dr. Tamara Maes, Chairman of the Scientific Advisory Board of Oryzon, (Netherlands)
Tamara Maes holds a Ph.D. in biotechnology (GENETICS) from the University of Ghent (Belgium). She was a member of the Scientific Advisory Board of the Spanish National Research Council (CSIC) from 20 January 2009 to 22 January 2013, has Chair been a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation (ADDF) since 2016
Speakers:
Dr. Marc Ferrer, MD, PhD. Coordinator of the Comprehensive Care Programme for Borderline Personality Disorder (BPD) for adolescents and young adults at the Vall d’Hebron University Hospital. (Spain)
Dr. Marc Ferrer is a doctor in Psychiatry and Clinical Psychology. He is the Coordinator of the Comprehensive Care Programme for Borderline Personality Disorder (BPD) for adolescents and young adults at the Vall d’Hebron University Hospital. He works and does research on BPD in adolescence and adulthood, ADHD, and Dual Pathology.
Dr. Clara Tang. Director of Research at the Kabuki Syndrome Foundation (UK)
Ph.D. in neuroscience from the University of Cambridge. She is the Director of Research at the Kabuki Syndrome Foundation. Dr. Tang is responsible for leading the development and execution of the Kabuki syndrome research strategy. Kabuki Syndrome Foundation is a non-profit organization dedicated to accelerating research efforts to treat or cure Kabuki syndrome.
Dr. Siddharth Banka, MBBS, MRCPCH, PhD, Manchester Centre for Genomic Medicine (Manchester University NHS Trust) as a Consultant Clinical Geneticist (UK)
Clinician Scientist who combines genomics with functional and clinical studies in rare human genetic disorders. He holds a joint position at the Manchester Centre for Genomic Medicine (Manchester University NHS Trust) as a Consultant Clinical Geneticist. In his clinical practice, he sees children and adults with a range of genetic disorders.
16:30 – 17:00
Participants
- Palobiofarma, Santiago Figueroa, COO
- Bold Therapeutics, E. Russell McAllister, CEO
- Gyala Therapeutics, Santos Claudio, Chief Executive Officer
- MedBioinformatics Solutions, Felix Slager, CEO
- Remab Therapeutics, Pablo Madrazo, CEO and Co-founder
- ZeCardio Terapeutics, CEO, Davide D’Amico
16:30 – 17:30
Sponsor
Abstract
There is a strong public debate on how to promote competitiveness and further European integration in the context of economic and geopolitical uncertainty. Major European initiatives are addressing this topic and the Spanish Presidency will mean a definitive push to define a common European perspective.
Faced with geopolitical shifts, and huge regulatory challenges, the EU must work towards maintaining competitiveness of the European Industry, foster strategic autonomy and create space and opportunities for innovative companies to move forward and become world leader for groundbreaking ideas.
This objective can only be achieved if industry and political stakeholders engage a franc dialogue and exchange some views on how to make Europe a more self-reliant region in the medium term.
Introduction:
- Albert Castellanos Maduell, Secretary of Business and Competitiveness of the Government of Catalonia
Moderator:
- Claire Skentelbery, General Director, EuropaBio (Belgium)
Speakers:
- Susana Solís, Member of European Parliament (Spain)
- Kristin Schreiber, Director, Directorate Ecosystems I: Chemicals, Food, Retail, Health in DG GROW, the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (Germany)
- Fernando Borredá Juste , Ministry of Industry (Spain)
- Teresa Rodó, EVP, Head of Global Healthcare Operations at Merck Group (Spain)
Closing Remarks:
- Manuel Zafra Rubio, President, Merck in Spain (Spain)
Sponsor
Abstract
The panel will discuss the current challenges on the development of innovative drugs in mental health and the feasibility to approach the unmet medical needs faced with a personalized approach. Some topics discussed will be:
- Prevalence and impact of mental conditions on the current society
- Challenges in clinical investigation in Mental Health
- Current innovations in depression, personality disorders, and psychotic disorders.
- The need to understand and focus on the patient. Roles of Patient Advocacy Groups
- Advances in understanding and treating Neurodevelopmental disorders (NDD)
- Can we learn from NDD to accelerate personalized medicine in mental disorders?
- BPD as an example of the difficulty of psychiatric diseases. Is BPD treatable?
Session sponsor: ORYZON
Moderator:
- Dr. Tamara Maes, President of Oryzon, (Belgium)
Tamara Maes holds a Ph.D. in biotechnology (GENETICS) from the University of Ghent (Belgium). She was a member of the Scientific Advisory Board of the Spanish National Research Council (CSIC) from 20 January 2009 to 22 January 2013, has Chair been a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation (ADDF) since 2016
Speakers:
Dr. Marc Ferrer, MD, PhD. Coordinator of the Comprehensive Care Programme for Borderline Personality Disorder (BPD) for adolescents and young adults at the Vall d’Hebron University Hospital. (Spain)
Dr. Marc Ferrer is a doctor in Psychiatry and Clinical Psychology. He is the Coordinator of the Comprehensive Care Programme for Borderline Personality Disorder (BPD) for adolescents and young adults at the Vall d’Hebron University Hospital. He works and does research on BPD in adolescence and adulthood, ADHD, and Dual Pathology.
Dr. Clara Tang. Director of Research at the Kabuki Syndrome Foundation (UK)
Ph.D. in neuroscience from the University of Cambridge. She is the Director of Research at the Kabuki Syndrome Foundation. Dr. Tang is responsible for leading the development and execution of the Kabuki syndrome research strategy. Kabuki Syndrome Foundation is a non-profit organization dedicated to accelerating research efforts to treat or cure Kabuki syndrome.
Dr. Siddharth Banka, MBBS, MRCPCH, PhD, Manchester Centre for Genomic Medicine (Manchester University NHS Trust) as a Consultant Clinical Geneticist (UK)
Clinician Scientist who combines genomics with functional and clinical studies in rare human genetic disorders. He holds a joint position at the Manchester Centre for Genomic Medicine (Manchester University NHS Trust) as a Consultant Clinical Geneticist. In his clinical practice, he sees children and adults with a range of genetic disorders.
Sponsor
Abstract
In recent years, the concept of open innovation has gained momentum, challenging traditional closed-door research approaches and proving to be catalysts for groundbreaking advancements in life sciences and medical technologies.
This panel brings together experts and leaders from diverse backgrounds to explore the concept of Open Innovation Test Beds and their transformative power to accelerate the development of novel solutions, at the crossroads of nanotech, medtech and life sciences.
Moderator:
- Anaïs Le Corvec, CEBR at Council of European Bio Regions (France)
Speakers:
- Ms. María Rodríguez Cañón, PhD, Biomedical Engineer, Neurostech (Spain)
- Mr. Alexandre Ceccaldi, General Secretary of the European Technology Platform for Nanomedicine (France)
- Ms. Iraida Loinaz, Director of the CIDETEC Institute for Nanomedicine at Fundación CIDETEC– Coordinator of TBMED OITB, (Spain)
The activity is part of the Project SafeNMT funded by the European Commission.
17:00 – 18:00
Sponsor
Abstract: The world of innovation in healthcare is currently facing an atypical moment where the macro-economy puts our industry under tension. This panel will aim to discuss i) the root causes of the challenging macro-economy and its consequences on the ecosystem of innovation in healthcare (“where are we”), ii) the projected short to mid-term evolution of the world economy (“what can we expect”), and iii) discuss rising opportunities allowing young startups of the healthcare ecosystem to adapt (“how do we adapt”).
Moderator:
- Sylvain Sachot, Partner at Asabys Partners (Spain)
Panelists:
- Nuria Mas, Professor of Economy, Jaime Grego chair of Healthcare Management, IESE Business School (Spain)
- Joachim Vogt, Director, Search and Evaluation International at Abbvie (Country)
- Susana de Antonio, Head of Listing Spain, Euronext (Spain)
- Myriam Rouis, Senior Investment Manager/Advisor – EIC Fund – Venture Capital (Luxembourg)
- Elena Lovo, Executive Director, Healthcare Investment Banking, J.P Morgan(UK)
17:30 – 18:00
Sponsor
Participants:
- Biodriven Technologies Álvaro Castellanos Caro, Business Developer
- Bread Free , Daniel Gómez-Bravo, CEO
- Ingredalia S.L, Miguel Angel Cubero Marquez ,CEO
- Oscillum, Luís Chimeno, CEO
- Protiberia, Ana Isabel Gonzales, CEO
17:30 – 18:30
Sponsor
Abstract
Join a round table discussion on how to further foster collaborative public-private environments which have become so prevalent as of late. The potential of these public-private partnerships will be illustrated with a success story whose protagonists are Lilly, from the pharmaceutical industry, CNIO (the Spanish National Cancer Research Center) and BSC (the Barcelona Super Computing center) whose joint action in the fields of with genetic, pharmacological and computational approaches have led to the identification of precision therapies in pancreatic cancer.
This is a splendid example on the potential of combining Artificial Intelligence and computational models with biomedical research in the development of organoids.
Session sponsor: Lilly
Moderator:
- Belén Marzo, Health Sectorial Leader | NextGenEUFI Group (Spain)
Speakers:
- Juan Ángel Velasco, Scientific Director of the Research Center at Lilly (Spain)
- Mariano Barbacid, Director of the Experimental Oncology Group of the National Cancer Research Center(CNIO), (Spain)
- Alfonso Valencia, Director of the Department of Life Sciences at the Barcelona Supercomputing Center ( BSC) (Spain)
18:00
20:15 – 22:00
Sponsor
Venue: Museu Nacional d’Art de Catalunya
Palau Nacional, Parc de Montjuïc, s/n, 08038 Barcelona
Dress Code: Smart casual
About the venue
The Museu Nacional d’Art de Catalunya is located in the Palau Nacional of Montjuïc, constructed for the International Exposition of 1929. In 1934 it opened its doors as the Museu d’Art de Catalunya, bringing together the medieval collection. Subsequently, in 1995, then as the Museu Nacional d’Art de Catalunya, the new rooms of Romanesque art were inaugurated, and in a successive way the public presentation of the collection was extended, a process that ended in 2004 with the integration of modern art.
Wednesday, September 27, 2023
08:30
Registration Open & Badge pick-up
09:30 – 10:15
Abstract
In the keynote speech, «Charting the Future: Reforming EU Pharmaceutical Legislation for Health and Innovation,» we explore the pivotal role of the European biotech pharmaceutical sector and the transformative potential of biotech-based solutions in revolutionizing healthcare. Highlighting the sector’s pioneering research, innovation, and economic impact, we emphasize the promise of precision medicine, rare disease treatments, sustainable pharmaceuticals, and global leadership. The speech underscores the necessity of reforming EU pharmaceutical legislation, advocating for streamlined approvals, concrete incentives for research and innovation, collaboration, accessibility, and environmental responsibility. The European biotech sector stands as a beacon of hope, charting a path to a brighter, healthier, and more innovative future for all.
09:30 – 10:30
Sponsor
In this round table we will highlight the barriers and difficulties of the technology transfer system towards spinoff creation.
At the same time, we will explore which are the lessons learned and policies to implement to turn our ecosystem into a benchmark in technology transfer and spinoff creation.
We will have leading people in our ecosystem: spinoff CEOs, investors, KOL in innovation both at an academic level and at a hospital and health level.
Moderator:
- Natalia de la Figuera, (COO GENESIS Biomed)
Speakers:
- Luis Villarrubia Grande, Coordinator DIH·bio, Universidad Autónoma de Madrid (Spain)
- Andreu Climent, CEO Corify Care (Spain)
- Laura Soucek, CEO Peptomyc (Spain)
- Josep Lluís Sanfeliu, Partner at Asabys (Spain)
- Eduard Soler, Head of innovation at Institut d’Investigació i Innovació Parc Taulí (Spain)
- Javier Etxabe, Head of Industrial Property and Entrepreneurship Support Area- CSIC (Spain)
10:15 – 11:00
Sponsor
Abstract
The European life sciences ecosystem is in the middle of a crossroad. Recently major policy changes have been announced such as the proposal for a new EU Pharmaceutical Legislation published in May by the EC. This once-in-a-life-time overhaul sets the framework of the European life sciences ecosystem for the next 20 years.
The panelists will share their vision on the impact this changing landscape will have on the European innovation ecosystem for biopharmaceuticals and discuss on the strengths Europe can leverage on to continue delivering life-saving innovations for the benefit of patients.
Moderator:
- Fina Llados, General Manager Spain & Portugal Amgen (Spain)
Speakers:
- Vlad Olteanu, Healthcare Public Affairs Director, EuropaBio (FRANCE/ROMANIA)
- Georges Siotis, Associate Professor of Economics – Universidad Carlos III Madrid and CEPR Research Affiliate; former Chief Economist Team – DG COMP, EC. (GREECE)
- Carlos Buesa, CEO – Oryzon Genomics. (SPAIN)
- Caridad Pontes, Pharmacy and Medicines Manager, Catalan Health Service – CatSalut (Spain)
The debate table will follow Mr. Vlad Oltealmu’s introductory presentation, from 9:30 to 10:00, on the legislative proposal of the European Commission released last May, 2023.
Sponsor
Abstract
Advanced therapies are medicines for human use that are based on genes, tissues or cells. They offer cutting-edge opportunities for the treatment of disease and injury. They include a complex and innovative class of biopharmaceuticals that are highly research-driven, characterised by innovative manufacturing processes and heterogeneous with regard to their origin, type and complexity. Moreover, these therapies often developed SMEs university and academia with limited regulatory experience.
ATMPS include Medicinal products based on cells or genes which are very different from medicines based on chemical entities or biological / biotechnological origin but are still subject to the same requirements of safety and efficacy. Attrition rates in the regulatory process are disappointingly high.
In this session we will count with:
- Asphalion, a leading Spanish scientific and regulatory consultancy services firm with ample experience in the regulatory process of ATMP and member of ARDAT consortium.
- AEMPS representative who will explain how the Committee for Advance Therapies supports academic research groups and pharmaceutical companies are to foster the development of safe and effective ATMPs.
- Hospital Clinic researcher with experience in the development of ATMP and access to the clinics.
- Splice Bio, who has a proprietary Protein Splicing platform that it is applying to the develop the next generation of gene therapies.
- Spark therapeutics, an international biotech company leader in the development of gene therapy.
Purpose: This session will center around regulatory insights to accelerate developed of ATMP with a focus on recent experiences coming from Spanish biotech companies and regulatory experts.
Moderator:
- Christopher Mann, Scientific & Regulatory Associate Director at Asphalion (Spain)
Speakers:
- Sol Ruiz, Head of division for Biological Products. Advanced Therapies and Biotechnology AEMPS/EMA (Spain)
- Manel Juan Otero, Head of inmunology Department at Hospital Clinic (Spain)
Miquel Vila-Perelló, PhD, CEO, Splice Bio
- Yemisi Corinaldi, Regulatory Affairs Leader at Spark Therapeutics (UK)
Sponsors
Abstract
Patent cliffs and depleted pipelines are a permanent threat for the pharmaceutical industry. Open innovation programs integrate internal and external expertise and afford the opportunity to tap into early-stage R&D in an approach that allows significant derisking of projects. In this round table representatives of pharmaceutical companies and Canadian venture capital firm iCan Partners will share experiences in open innovation, and we will explore the potential of Spanish R&D system to contribute to fuller drug pipelines.
Government direct investment promotion agency, Invest in Spain, will also provide an overview on the instruments used by the government to encourage Open Innovation programmes.
Moderator:
- Alberto Sanz Serrano, Director of Finance and Investor Relations at Invest in Spain (Spain)
Speakers:
- Markus Koch, Disease Biology Executive Director at Almirall (Spain)
- Emilio Erazo-Fischer, Director BD&L Oncology, Boehringer Ingelheim
- Dr. Lorena Tora, Chief Medical Officer de iGan Partners (Canada).
- Ms. Keiko Kobayashi, Startup/Drug Discovery and Biomedicine Group Chief Coordinator at Foundation for Biomedical Research and Innovation at Kobe (FBRI) (Japan)
10:15 – 11:00
Sponsor
Participants
- NEUROFIX PHARMA, Jascha Blobel, Chief Business Officer/ Antonio Oliviero, Chief Medical Officer
- Biointaxis S.L., Antoni Matilla Dueñas, Cofounder and Director
- D-Sight, Carla Maté Goldar, CEO&Co-founder
- INCLIVA, Piotr Konieczny, Postdoctoral researcher
- Laminar Pharmaceuticals / LAM561 for newly-diagnosed Glioblastoma
- Javier Fernández Díaz, BD Manager and CSO Associate
11:00 – 11:30
Coffee Break
11:30 – 12:30
Sponsor
Title:
Patient’s voice as starting and ending point for the development of new innovative healthcare solutions
Abstract:
New science, new technologies, new challenges and the constant and fast change are impacting more than ever, the way we discover, develop and provide new health-care solutions to people that suffer a disease. The complexity of this new constellation of innovation can easily eclipse what all this effort is truly for. We bring the voice of the patient, the start and the final objective of what we do in drug development, to share their perspective, their expectations, their role and their potential contribution about what is needed for designing, investigating and providing new solutions for their real problems. We will engage in this panel also, the voice of the new digital technologies in healthcare, the perspective of the clinical experts and the voice of the Pharmaceutical Sponsors, in order to discuss together about how this collaboration, co-creation, with the patients could be stablished.
Session sponsor: ESTEVE Healthcare
Moderator:
- Jose Maria Gimenez Arnau, Chief Scientific & Medical Officer, ESTEVE Healthcare
Speakers:
- Fulvio Capitanio, Associació Catalana de Malalts de Parkinson
- Begoña Nafría Escalera, Patient engagement & Research coordinator, Hospital Sant Joan de Déu, Barcelona. Coordinator eYPAGnet
- Montse Barcelo Riera, VP Europe Veristat
Sponsor
Abstract
Biological therapeutics (biologics) are revolutionizing the treatment of cancer and immune inflammatory disease states. Initially, biologic drugs were limited to simple peptide molecules (e.g., insulin). However, in recent years, with the progression of innovative technological approaches, biologics comprised of monoclonal antibodies, fusion proteins, vaccines, cell and gene therapies have been created and deployed in the treatment of disease. However, not all biological reagents are created equal. Different diseases require different targets and different assays, and off-the-shelf reagents may not always be suitable for a particular application. This is where tailored solutions come into play. Tailored solutions of biological reagents are custom-made to fit specific research needs. They are designed to meet the exact specifications required for a particular application, ensuring maximum specificity, sensitivity, and accuracy. This is particularly important in biomedical medicine research, where the ability to accurately identify and target specific biomolecules is crucial.
Moderator:
- Iván Marcos, PhD, MBA, Strategic Collaborations Manager Promega Biotech Ibérica, S.L. (Spain)
Speakers:
- Francisco Castillo, Sr Scientist Screening and Target Validation, Fundación MEDINA ( SPAIN)
- Tom Livelli, VP, Life Sciences Products & Services, Promega Corp. (Madison, WI-USA)
- Carles Celma, PhD, Innovation Director, KYMOS S.L. (Spain)
Sponsor
Context
Infections caused by antibiotic-resistant bacteria kill 1.2 million people worldwide every year, more than AIDS, malaria and some respiratory tract tumors.
This pandemic has been unfolding for years and threatens to become a major threat to health, but also to food security or agriculture. It is estimated that in less than 30 years superbugs will kill 10 million people each year, that is, three times more than the estimate for covid in 2020.
This pandemic also faces obstacles to the development of new antibiotics that address the growing threat of microbial resistance, as there is a long road to approval, high cost, and low success rates.
INTRODUCTION:
- TBC
Moderator:
- Cristina Nadal, Executive Policy Director MSD (Spain)
Speakers:
- Juanjo Infante, CEO, VAXDYN
- Paul Schaper, Associate Vice President, Global Public Policy, MSD
- Carles Nieto, Global Head of Science, Reig Jofre (Spain)
Manuel Garcia Goñi, Vice Dean for International Affairs, Faculty of Economics and Business, Universidad Complutense de Madrid (Spain)
Sponsor
Abstract:
BCN Health Booster is a 3-year program aimed at companies in the health sector to be accelerated by accessing a laboratory in the Barcelona Science Park and a specialized acceleration program taught by Biocat.
BCN Health Booster is an initiative of the Barcelona City Council, the Barcelona Science Park, Barcelona Activa and Biocat.
Now the halfway point of the program is over, we present the main indicators of the acceleration and speak with 3 participating companies to share how their project has evolved, what their challenges and needs are and what the program has contributed to help them in aspects as relevant as product development, project financing, team growth or intellectual protection.
Summary of the first one and a half years of the accelerator
Speaker:
- Maria Terrades, CEO Barcelona Science Park (Spain)
Presentation of the acceleration program and Key Performance Indicators (KPIs) of the startups, remarkable milestones and relevant information outcomes of the startups participating in the program during 2022.
ROUNDTABLE
Moderator:
- Núria Martí, Director of Innovation, Biocat (Spain)
Speakers:
- Mercè Frias, COO Ona Therapeutics (Spain)
- Marina Rigau, CEO & Co-founder Mimark (Spain)
- Gisela Lorente, CSO Aptadel Therapeutics (Spain)
Closing of the session and promotion of pitch showcase
Speakers:
- Núria Martí, Director of Innovation, Biocat (Spain)
Invitation to assist to the pitch session of Barcelona Health Booster startups Date 27th september from 4:30 pm to 5:30 pm at the BioRegion of Catalonia pavilion.
12:00 – 12:30
13:00 – 13:45
Sponsor
Abstract
In 2021 the European Union launched an initiative to deepen cooperation on health technology assessment in which was undertaken by the EUnetHTA 21 joint consortium integrated by several European HTA agencies. The project is a first step in the development of a future EU HTA system.
Further regulatory harmonization in the EU is also being addressed through the Clinical Trials Regulation applicable since 2022. The aim of these new guidelines is to ensure the EU offers an attractive and favorable environment for carrying out clinical research on a large scale, with high standards of public transparency and safety for clinical trial participants.
The Regulation provides a transparent and inclusive framework by establishing a Coordination Group of HTA national or regional authorities, a stakeholder network and by laying down rules on the involvement in joint clinical assessments and joint scientific consultations of patients, clinical experts and other relevant experts.
In this round table we analyze how the new framework will bear upon the already challenging standards required to bring ATMP, and more specifically cell therapies, to the patient.
Moderator:
- Chus Castillo, Partner Consulting CSG Iberia, Alira Health (Spain)
Speakers:
- Robert Fabregat, General Manager Biocat HUB Advanced Therapies Cataluña (Spain)
- Isabel Pineros, Director of Access Department at Farmaindustria (Spain)
- Gonzalo Calvo Rojas, Coordinator of Advanced Therapies and Head of the Department of Clinical Pharmacology, Hospital Clinic de Barcelona . (Spain)
- Marisolo Montolio, Global Alliances Manager. Regional Manager, Europe at Lymphoma Coalition (Spain)
- David Beas, GA&MA Director Jansen (Spain)
Sponsor
Participants
ABAC Therapeutics S.L., CEO, CSO Domingo Gargallo-Viola
- The Foundation for the Promotion of Health and Biomedical Research of Valencia Region, FISABIO, María D. Ferrer,Innovation Agent
- Instituto de Química avanzada de Cataluña, Pilar Marco, Head of the NB4D group
- IQM, Fernando Herranz- Researcher in Nanomedicine and Molecular Imaging
- I2SysBio, Pilar Domingo-Calap, Ramon y Cajal Researcher and group leader
- Mikrobiomik , Juan Basterra, CEO
- Pragmatech AI Solutions Javier Fernández Domínguez, Founder,
- Pulmobiotics SL , María Lluch Senar, Co-founder and SCO
- VAXDYN, Juanjo Infante, CEO
Sponsor
Abstract
The Biotechnology Sector is fundamental in the progress and advancement of economic activity, safety and quality of life of Spanish society. It is a meeting point between Science and Technology, which allows the development of specific solutions aimed at safeguarding the health of the population, while bringing Spain closer to the forefront of innovation, thanks to the presence and activities that companies in this sector carry out every day.
Most biotechnology companies are SMEs and startups that do not have products on the market and, therefore, do not generate the resources to finance their activities. Due to this, access to external financing is key to the development of the biotechnological ecosystem and one of the priorities in the current regulatory framework.
In this round table we will talk about the different forms of investment and incentives for R + D + i in the biotechnology industry in Spain.
Moderator:
- Cristina Cortés, Innovation Manager de Ayming
Speakers:
- Jordi Xiol, Partner, Ysios (Spain)
- Virginia González, CEO, QUNUBUS Pharmaceutical S.L (Spain).
- José Bayón, CEO at ENISA- Spanish National Innovation Company (Spain).
Sponsor
Abstract
The bioeconomy is committed to an economic model aimed at maximizing resource efficiency through the utilization of bio-based raw materials and the implementation of circular production processes, which not only minimize waste but also generate new avenues for its utilization.
Moreover, the bioeconomy plays a pivotal role in addressing pressing societal concerns such as food safety, climate change, and the accessibility of clean and affordable energy. Furthermore, it accelerates our advancement towards achieving the Sustainable Development Goals (SDGs) outlined by the United Nations.
In this session, our objective is to delve into the essential requisites, challenges, and opportunities that necessitate careful consideration for the promotion of the bioeconomy within the European context.
Moderator:
- Bosco Emparanza, CEO at MOA biotech S.L
Speakers:
- Javier Mena – Scientific Coordinator at Clamber R&D Biorefinery (Spain): will provide a perspective about the operating in the bioeconomy sector. They will share their entrepreneurial journey, successes, and obstacles faced. They will shed light on the unique challenges faced by SMEs in the bioeconomy and the opportunities they can leverage.
- Sergi Rodà – Project manager at Nostrum Biodiscovery (Spain): will provide a perspective about the operating in the bioeconomy sector. They will share their entrepreneurial journey, successes, and obstacles faced. They will highlight recent advancements, emerging technologies, and the potential of scientific collaborations in driving the bioeconomy forward.
- Manel Porcar – CEO at Darwin Bioprospecting (Spain): will provide a perspective about the operating in the bioeconomy sector. They will share their entrepreneurial journey, successes, and obstacles faced. They will highlight recent advancements, emerging technologies, and the potential of scientific collaborations in driving the bioeconomy forward.
13:45 – 15:00
Lunch break
15:00 – 16:00
Sponsor
Abstract
In the dynamic and competitive pharmaceutical industry, developing capabilities is essential for companies to maintain a competitive edge and achieve long-term growth. Mergers and acquisitions (M&A) have emerged as a successful strategy employed by many pharmaceutical companies to achieve this. However, when it comes to acquiring new technologies, there is inherent risk in doing so without a comprehensive understanding of their potential and market viability. Selecting the most promising technologies also presents a challenging decision. As a result, pharmaceutical companies often opt for building collaborations, partnerships, or making equity investments to test the waters before a M&A transaction.
Moderator:
- Jose Terencio, GRIFOLS – GIANT (Spain)
Speakers:
- Dirk Büscher, GRIFOLS – GIANT (Spain)
- Benjamin Turner, Associate director, Venture Science at Eli Lilly (UK)
- Sabin Minguez, R&D Worldwide Business Development, GSK (Spain)
- Louise Warme, Head of We venture capital, WERFEN
Abstract
There is a pipeline of gene therapies currently in clinical studies which rely on viral vector systems, which are challenging to manufacture cost-effectively at a commercial scale. In addition, new non-viral vectors, such as polymers, lipids, inorganic particles, and combinations of different types thereof have shown promising results in recent years. Although, non-viral vectors have low cytotoxicity, immunogenicity, and mutagenesis and are attracting the attention of the industry they are not exempt of pitfalls.
Purpose: Contrast vector technologies for gene therapies which are showing promise. Showcase the technological capabilities of the Spanish biotech ecosystem in the development of ATMP.
Moderator:
- Ramón Martínez Máñez, Full Professor at the Polytechnic University of Valencia and Scientific Director of CIBER-BBN, (Spain)
Speakers:
- María Jesus Vicent, Research Scientist at CIPF. Principal Investigator of Polymer Therapeutics Laboratory-CIBERONC (Spain)
- Mariana Köber, Research Scientist at ICMAB-CSIC. Principal Investigator of NANOMOL-CIBER-BBN (Spain)
- Avencia Sánchez-Mejías, CEO at Integra Therapeutics (Spain)
Competitors
- Aortyx, Jordi Martorell,CEO
- CORIFY CARE SL, Andreu Climent, CEO
- Eterna diagnostics, Marcos Ladreda, MSc , CEO
- Flomics Biotech Joao Curado, CEO
- Neuroscience Innovative Technologies SL (NEUROSTECH) Gabriel Alvarez, CEO,
- Sequentia Biotech Walter Sanseverino, CEO
- BeCytes Biotechnologies , Estephan Arredondo, CTO
- EXHEUS, Teresa Tarragó, Director and Co- founder
Sponsors
Abstract
Traditional drug discovery relies on screening thousands of molecules in the hopes of identifying a druggable entity. Often the mechanism of action is not known or well-understood. This process is costly and time consuming. In contrast, rational drug design is a scientific approach that relies on the biological target characterization to design a molecule specifically targeting and treating the disease. This approach should lead to the development of more effective drugs with fewer side effects. This session will illustrate how Spanish biotech companies are approaching rational drug design and novel platforms for drug discovery.
Moderator:
- Pablo V. Escriba, CEO Laminar Pharmaceuticals (Spain)
Speakers:
- José María Giménez Arnau, Chief Scientific & Medical Officer Esteve (Spain)
- María Majellaro, Chief Scientific Officer at Celtarys (Spain)
- Lucía Díaz Bueno, Director of Drug Design at Nostrum Biodiscovery (Spain)
- Jordi Hernandez, Principal, Alira Health (Spain)
16:00 – 16:30
16:30 - 17:30
Sponsors
Abstract
The amount of health data is growing exponentially and the industry stakehholders are struggling to implement strategies and scale their capabilities to unlock its full value. The upcoming EHDS, a harmonized framework of rules, standards and practices, infrastructures and governance, will add challenges, but also create huge opportunities that this panel, organised by the EU-funded project, EDAH, will explore. The panel will analyse the barriers and drivers to deploy the potential of the secondary use of health data and the readiness of the industry to be engaged and contribute to this transformation. The strategies put in place by the sector leaders across the EU will also be addressed in this engaging round table that will provide insightful strategies, take-home learnings and dynamic exchanges among experts and attendees.
Moderator:
- Montserrat Daban, Director of Science Policy and Internationalization and President of Council of European BioRegions (CEBR) and member of HERA’s Joint Industrial Cooperation Forum (Spain)
Speakers:
- Antonio Alcolea, Deputy Director General of Data Economy and Digitization (Secretary of State for Digitization and Artificial Intelligence) at the Ministry of Economic Affairs and Digital Transformation (Spain) (TBC)
- Cristina Nadal, Policy Executive Director MSD (Spain)
- Sergio Muñoz, Chief Innovation Officer and Digital Health and Emerging technologies Director in FENIN (Spain)
- Petri Lehto, Senior Lead, Health data 2030 at SITRA (Finland)
- Iza Alfany, Managing Director at EIT Health (Spain)
Sponsor
Abstract
In the European Union, public procurement accounts for about 20% of the GDP of the 27 member states, that is, more than 3 trillion euros each year. This data positions public administrations as a first-rate economic agent with unmatched purchasing power in the private sector. With this enormous spending capacity, governments could achieve a high impact on the development of innovative companies and products.
IPP make it possible to compensate for a «market gap» characteristic of high-tech sectors. On the one hand, the demand sends mixed signals and is not capable of transmitting its true needs. On the other hand, in times of economic and social crisis, investors and entrepreneurs are less willing to take risks. For small and medium-sized enterprises (SMEs), the problem is even more pressing, as they have difficulties in obtaining the necessary financing to be innovative. This situation hinders the development of new markets and products.
IPP can have a huge impact on technological progress, since companies could make a technological bet knowing that they have a client that will ensure their sales. Initiatives of this type could introduce important improvements in public services and at the same time reduce the risk of investment in innovation and development.
This session will analyze the experiences on PPI/PPP in the Spanish/European ecosystem through instruments such as the FID line (https://www.ciencia.gob.es/Innovar/CPI-LineaFID.html ) or the Horizon Europe and its execution in projects financed by the Autonomous Community of Andalucía. In addition, new initiatives within the framework of the post-pandemic recovery plans will be discussed.
Speakers have been carefully selected to be able to provide a 360 vision of the Innovative public procurement process so attendees can understand deeply the whole process. Including main challenges and barriers and how to overcome them. They will also share their broad experience focusing on the improvement of future programs based on their accumulated experience.
Moderator:
- Diego Moñux Chercoles, Co-founder at SILO (Spain)
Speakers:
- Amanda Gil Sánchez, Deputy Director General of Promotion of Spanish Ministry of Science and Innovation’s (Spain)
- Iván Macía Oliver, Director of Digital Health & Biomedical Technologies (Spain)
- Esther Martínez Álvarez, manager at SILO (Spain)
- German Gutierrez, Integrated Health Solutions Business Director in Medtronic Iberica (Spain). A global healthcare technology leader — boldly attacking the most challenging health problems facing humanity with innovations that transform lives.
Sponsor
Abstract
This session will serve as the ceremony to the Merck Advance Biotech Grant. Speakers will share how they support biotech startups from discovery to commercialization.
After the speakers, preselected finalist companies for the Advance Biotech Grant will present their business proposition. The winner will be announced at the end of the presentations.
Merck understands the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why Merck has developed their Advance Biotech Grant programs which occurs on regular basis in different regions of the world. These programs awards grant recipients with products, services and consultation support to advance production and help accelerate their path to commercialization.
The session will includes pitch presentations from the finalists and will conclude with an award ceremony.
Speakers:
- Iñigo de la Fuente, Customer Application Consultant Emerging Biotech – South EMEA, Life Science | Process Solutions, MERCK
- Marta Diez Castellnou, Emerging & Biotech Inside Sales Account Manager, Life Science | Science and Lab Solutions, MERCK
Abstract
In a world grappling with increasingly pressing energy challenges, biotechnology is emerging as a transformative force in the transition towards cleaner and more sustainable energy sources. This roundtable will delve into the pivotal role that biotechnology plays in crafting innovative solutions for energy generation, funding, storage, and distribution. From bioengineering microorganisms for biofuel production to the application of enzymes and genetically modified organisms in biomass conversion, this discussion will highlight how biotechnology is paving the way for a greener and more promising energy future. Join us in an enriching dialogue on how biotechnological science and technology are driving the shift toward a more sustainable, lower-carbon world.
Moderator:
- Begoña Ruiz, Director of Technology at AINIA (Spain)
Speakers:
- María Pilar, Gonzalez Gotor , Department Head to the Department of Institutional Promotion and Territorial Cooperation at CDTI (Spain)
- Adriana Orejas Núñez, Director of Industrial Transformation Technology at Repsol (Spain)
- Javier Gil Barno, Director Biomass Department at CENER (Spain)
- Caterina Col, CEO at Perseo Biotech (Spain)
17:30 - 18:15
Sponsor
Participants
- Ability Pharmaceuticals SA,Carles Domènech, CEO
- Gate2Brain, Meritxell Teixidó, CEO
- Immunocoaching , Joan Ballesteros, Chairman & CSO
- InnoUp Farma, Maite Agüeros, CEO
- Leadartis , Juanjo Perez Villar, CEO
- Nanoligent SL ,Montserrat Cano, CEO
- Oniria Therapeutics , Esther Riambau, CEO
17:30 - 18:30
Sponsors
Abstract
The Spanish Government funded and regionally executed ‘Plan Complemetario de Biotecnología Aplicada a Salud’ is developing new tools for diagnosis, prognosis, advanced or targeted therapies in the field of personalized medicine. This round table explains how the industry can benefit from the new tools and how they can lead to the establishment of public-private partnerships. In this table we invite four representatives from centers out of the more than thirty representing the seven Spanish regions participating in the consortium.
Moderator:
- Teresa Sanchis , Head of Strategy, Institute for Bioengineering of Catalonia (IBEC) (Spain)
Speakers:
- Josep Samitier Martí, Director IBEC Institute for Bioengineering of Catalonia (Spain)
- Dra. Mari Luz Couce, directora del Instituto IDIS del ISCIII De Santiago (Spain)
- Jose María Mato de la Paz, General Director of CIC Biogune (Spain)
- Francisco Miguel Sánchez Margallo, Scientific Director, Centro de Cirugía de Mínima Invasión Jesús Usón (Spain)
Sponsor
Abstract
- Objective to address: How to substantially improve the use of the effort made in researching new drugs in Spanish public centers, achieving better success rates in terms of number of projects, time needed and investment required to reach the patient.
- Diagnosis: There is a critical phase that is the overcoming of regulatory preclinical research, in order to increase the interest of the pharmaceutical industry to engage in the continuation of the development of the project. Before this phase, the pharmaceutical industry tends to see excessive risks, but public research centers do not have the resources or adequate mechanisms to address it on their own.
- Measures to be deployed in a balanced way: The most obvious is, of course, the availability of funding to cover the costs of regulatory preclinical research, which in average terms would be estimated at between 3 and 4 million euros per completed project. But for the investment to be effective, first of all, a good selection of projects must be achieved, there must be an appropriate management instrument to continue with the project outside the public research entity (new spin-off company) and later a good informative and commercial action to get the involvement of pharmaceutical companies in the projects with the best expectations. This involvement is, ultimately, the final goal, since it will be the pharmaceutical companies that get involved in the clinical development of the projects that will have the capacity to bring the final therapy to the patients, at the same time managing to raise the importance and competitiveness of the pharmaceutical sector that operates in Spain. The result of the public-private effort contributed to this type of initiative requires a balanced return that benefits both the business environment and society as a whole.
Therefore, the five pillars to achieve a successful translation of results would be:
- a) sufficient economic funds to finance regulatory preclinical research;
- b) professional capacity for a good selection of projects;
- c) creation of new spin-off companies with good management skills and confidence in the project;
- d) appropriate mechanisms and skills to involve the pharmaceutical industry in successful projects;
- e) social and industrial balance in the return of expected benefits.
- The new recently created initiatives and the opinion of the agents: In view of the indicated scenario, a round table could be discussed where, first of all, the degree of consensus around the five noted pillars is contrasted. Secondly, to what extent the targeted initiatives (and perhaps add if there are any more in sight) are adapted to the needs-Country and why. And, thirdly, discuss whether in the thinking of the participants at the table there is the idea that these initiatives are going to represent a real change of direction or whether things will continue as they have been up to now.
Moderator:
Amelia Martín Uranga, Director of the Department of Clinical and Translational Research., Farmaindustria (Spain)
Speakers:
- Mabel Loza, Founding Member, Fundación Kaertor (Spain)
- Lourdes Nuñez, Director of Knowledge Transfer, Internationalization and Entrepreneurship, Parque Tecnologico de Salud Granada(Spain)
- Jose Miguel Vela, CSO & Sire manager at Welab (Spain)
- Raúl Martín , Partner at YSIOS (Spain)
- María Fernández, Market Access Director, Amgen(Spain)
Sponsors
Abstract
In a world where constant innovation is vital for the growth of companies, particularly those in the biotech sector, it is necessary to have multiple sources of funding in order to have sufficient resources to advance their research. In addition, smaller companies are financed at higher rates and sometimes find it more challenging to access sufficient funding, making the role of the junior stock markets fundamental in assisting companies to expand and develop their business projects.
Moderator:
- Jesús González Nieto-Márquez, Managing Director of BME Growth and BME SCALEUP (Spain)
Speakers:
- Roger Freixes, Partner Cuatrecasas (Spain)
- Isabel Lozano, CEO Atrys Health (Spain)
- Carlos Buesa, CEO Oryzon Genomics (Spain)
20:00 – 23:00
BIOSPAIN TAPAS ROUTE
September 28, Thursday
08:30
Registration Open & Badge pick-up
09:00 - 09:30
- Ion Arocena Vélez, General director at AseBio
- Ignacio García Fenol, Deputy Director General for the Promotion of Innovation at the Ministry of Science and Innovation
- Pere Aragonès i Garcia, President government of Catalonia
09:30 – 10:15
Sponsor
Abstract
The AstraZeneca Hub in Barcelona is the first co-located Research and Development Center that houses global teams across all of AstraZeneca’s and Alexion´s therapeutic areas: Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immunotherapies. This Hub is composed of multidisciplinary teams in clinical development, regulatory affairs, biometrics, IT and digital innovation, among others.
This R&D International hub aims to become one of Europe’s largest Hubs of clinical excellence and innovation. It will foster collaboration and open new opportunities with the Biomedical and Digital ecosystems locally, regionally, and globally.
This hub will advance science and innovation, by actively leading and participating in projects for future therapeutic solutions, accelerating drug development, increasing access, and bringing medicines worldwide faster, to treat patients earlier, with more efficacy and precision.
Up to 1,000 people are expected to be recruited by 2025, of which more than 250 are already onboarded between Alexion and AstraZeneca
Speaker:
- Gonzalo de Miquel, Vice President Therapy Area NF & Bone Metabolism at Alexion and Head of the AstraZeneca Barcelona Hub AstraZeneca (Spain)
09:30 – 10:30
Abstract
The AstraZeneca Hub in Barcelona is the first co-located Research and Development Center that houses global teams across all of AstraZeneca’s and Alexion´s therapeutic areas: Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Vaccines & Immunotherapies. This Hub is composed of multidisciplinary teams in clinical development, regulatory affairs, biometrics, IT and digital innovation, among others.
This R&D International hub aims to become one of Europe’s largest Hubs of clinical excellence and innovation. It will foster collaboration and open new opportunities with the Biomedical and Digital ecosystems locally, regionally, and globally.
This hub will advance science and innovation, by actively leading and participating in projects for future therapeutic solutions, accelerating drug development, increasing access, and bringing medicines worldwide faster, to treat patients earlier, with more efficacy and precision.
Up to 1,000 people are expected to be recruited by 2025, of which more than 250 are already onboarded between Alexion and AstraZeneca.
Speaker:
- Gonzalo de Miquel, Vice President Therapy Area NF & Bone Metabolism at Alexion and Head of the AstraZeneca Barcelona Hub AstraZeneca (Spain)
10:15 – 11:00
Sponsor
Abstract
An introductory presentation of employment trends and opportunities in the biotechnology industry. Which functions, sectors and profiles are in greater demand? Experts from the industry will help us identify opportunities.
Introduction:
- Montse Sanz Enguita, Responsible for Labor Market at Barcelona Activa
Moderator:
- Marga Santaeularia i Solans, Project coordinator at Barcelona Activa
Speakers:
- Tomás Alarcón, Human Resources Officer at 3PBiopharmaceuticals
- Michael Thiele, Partner at LIM Global
- Marc Soler, HR Director, Alexion
10:15 – 11:00
11:00 – 11:30
Coffee Break
11:30 – 11:45
11:30 – 13:45
11:30 – 12:30
Sponsor
Abstract
A career in biotechnology can be one of the most fast paced and thrilling professional experiences. It is also likely to be fraught with daunting challenges. You will have to learn about clinical trials, quality control and assurance, product development, regulatory affairs, or market access. You are likely to suffer disappointments, but you may also reap the rewards of getting a treatment for a rare disease approved. Biotech offers a wide range of job opportunities and a diverse workforce. Meet some of the most successful entrepreneurs and managers of the industry at this roundtable where they will share their experiences and biographies.
Moderator:
- David Álvarez Ordás, Director of Institutional Affairs at FEBiotec (Spain)
Speakers:
- Tamara Maes, President of the Scientific Advisory Board at Oryzon (Belgium)
- Isabel Portero, CEO at Biohope (Spain)
- Eva García Paino, Secretaria general at RAICEX (Spain)
12:30 – 13:15
Organized by
Abstract
The biotech industry is deeply reliant on the attraction and retention of highly qualified individuals. Attracting and retaining talent is not an easy task, especially for smaller companies, start-ups and companies located in peripheral regions. In this round table several experts will discuss strategies to build a talented and diverse workforce. Furthermore, some information collected by AseBio on women in the biotech sector, good practices and compensation benchmarking will be shared.
Moderator:
Tomás Alarcón, HUMAN RESOURCES DIRECTOR at 3PBiopharmaceuticals (Spain)
Speakers:
- Sergio García, Human Resources manager at 53Biologics (Spain)
- Paula Olazábal, Partner and D&I Officer Ysios (Spain)
- Eduard Blazquez, – HRBP Lead de AstraZeneca en Barcelona, (Spain)
